Hengrui Pharma and Glenmark Pharmaceuticals enter exclusive license agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)

CAR-T Digest - August 2020

24 September 2025: Hengrui Pharma and Glenmark Pharmaceuticals enter exclusive license agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)

Hengrui Pharma granted Glenmark exclusive rights (excluding major markets like China, US, EU, Japan) to develop and commercialize Trastuzumab Rezetecan (SHR-A1811), with a deal valued at up to US$1.111 billion (US$18M upfront + milestones + royalties)
Trastuzumab Rezetecan, Hengrui’s self-developed HER2-targeting ADC, was approved in China in may 2025 for HER2-mutant NSCLC and has a priority review for breast cancer as of september 2025
The ADC has received breakthrough therapy designation for nine indications in China, including NSCLC, breast, gastric/GEJ, colorectal, biliary tract, and gynecologic cancers
In August 2025, the US FDA granted orphan drug designation to the drug in combination with adebrelimab and chemotherapy for gastric/GEJ adenocarcinoma
Hengrui’s proprietary HRMAP ADC platform underpins a pipeline of over 10 differentiated ADCs, with 6 already in Phase 3 or later, positioning the company as a leader in ADC innovation in China